North America Gastroparesis Market Size and Competitive Analysis by 2027

The gastroparesis market in North America is expected to grow from US$ 1,488.03 million in 2020 to US$ 2,032.27 million by 2027; it is estimated to grow at a CAGR of 4.6% from 2020 to 2027.

The US, Canada, and Mexico are major economies in North America. Growing diabetes mellitus prevalence is the major factor driving the growth of the North America gastroparesis market. Diabetes mellitus is a life-threatening chronic disease mainly caused by the body’s inability to produce insulin or effectively utilize it. Diabetes is one of the health emergencies of the 21st century. According to a report published by International Diabetes Federation (IDF) in 2019, 1 in 11 people in the world are suffering from diabetes. In addition, the National Institutes of Health (NIH) also reported that the incidence of type 1 diabetes is increasing rapidly, and the disease is affecting a significant number of children and teenagers. Diabetes is one of the prominent known causes of gastroparesis. The condition is characterized by damaged nerves, especially involving vagus nerves and stomach wall cells. The damage to vagus nerves affects muscle motility of stomach and small intestine. According to a study published by Johns Hopkins University, ~30–50% of the diabetic population suffers from delayed gastric emptying. The escalating incidence of diabetes mellitus due to obesity, sedentary lifestyle, and unhealthy eating habits is propelling the prevalence of gastroparesis.        

Although the healthcare sector had witnessed SARS, H1N1, and other outbreaks in the last few years, the severity of the COVID-19 has made the situation more complicated due to its mode of transmission. North America has been witnessing a growing number of COVID-19 cases since its outbreak. In patients with chronic GI illnesses, COVID-19 may initially present as a flare of their underlying GI conditions as viruses have historically been implicated in exacerbations of GI disorders, including gastroparesis. Moreover, according to the world gastroenterology organization, there has been observed a rise in GI complications after COVID-19 symptoms. Patients with COVID-19 may complain of digestive symptoms such as poor appetite, nausea, vomiting, diarrhea, symptoms, or disease activity for pre-existing digestive diseases such as inflammatory bowel disease.However, according to a review of Diabetic Gastroparesis for the Community Pharmacist published in 2016, over 29.1 million people in the US have diabetes and have faced with the complications associated with the disease. Diabetes is the most common systemic disease that causes gastroparesis. Moreover, according to data published by National Center for Biotechnology Information (NCBI) in September 2020, nausea and vomiting from detailed consideration as symptoms of COVID‐19 is surprising as it can be an early presenting symptom. Thus, there has been observed a rise in the sale of prokinetic agents and antiemetic agents. However, due to disruption in supply chain and governmental orders restricting certain activities in response to COVID-19, including changes in on-site operations to reduce manufacturing capacity and implement social distancing, reductions in suppliers’ ability to source, ship raw materials in alignment with demands, work stoppages, slowdowns, and delays, the market may show a slowdown.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America gastroparesis market. The North America gastroparesis market is expected to grow at a good CAGR during the forecast period.

North America Gastroparesis Market Segmentation

North America Gastroparesis Market – By Type

• Idiopathic
• Diabetic
• Post-surgical
• Others

North America Gastroparesis Market – By Drug Class

• Prokinetic Agents
• Botulinum Toxin Injections
• Antiemetic Agent

North America Gastroparesis Market – By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

North America Gastroparesis Market, by Country

• US
• Canada
• Mexico

North America Gastroparesis Market - Companies Mentioned

• Allergan Plc
• ANI Pharmaceuticals, Inc.
• Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.)
• Cinrx Pharma, LLC (Cindome Pharma)
• EVOKE PHARMA
• Ipca Laboratories Ltd.
• Johnson and Johnson Services, Inc.
• NEUROGASTRX, INC.
• Pfizer Inc.
• TEVA PHARMACEUTICAL INDUSTRIES LTD

North America Gastroparesis Report Scope